Nanomedicine and targeted drug delivery

In recent years, nanomedicine - the application of nanotechnology in healthcare - has emerged as a powerful and versatile area of research and is rapidly developing with many promising opportunities in the medical sciences. Nanocarriers are being developed for pharmaceuticals for example, with uses in cancer treatment and in particular targeted drug delivery.

In nanomedicine, the materials are engineered at the nanoscale, with sizes ranging from 100 to 1000 nm, and can be used to perform specific biomedical tasks. These nanomaterials, such as nanoparticles, are often made from crosslinked polymer chains and can encapsulate therapeutic molecules for delivery within the body. Their small sizes give them unique properties, as they can interact with cells at a molecular level, and be designed to respond at specific times and locations, which can be directed to specific tissues or environments. Since the coronavirus disease (COVID-19) pandemic, nanoparticle-based drug delivery platforms have been widely studied - lipid nanoparticles were used in the vaccine to combat the virus. Being highly successful, and looking ahead, research and development in nanomedicine-based drug delivery is expected to keep growing, as the interest in more precise and effective treatments continues to rise. 

How can nanoparticles be used for drug delivery?

A significant challenge in conventional drug therapies lies in their limited solubility, which can reduce the effectiveness of a drug and cause harmful side effects. Nanoparticles offer a solution to this: they can encapsulate poorly soluble drugs, protecting them from degradation in the body, and this allows them to be carried safely to the targeted tissues. This localised delivery improves the drugs’ biodistribution, and reduces systemic toxicity, which is a common concern in treatments such as chemotherapy, where healthy tissues in the body are damaged. Nanoparticles in particular are exciting as they have tuneable surface properties and a high surface to area volume ratio. This means their physical and chemical behaviours can be adjusted - for example through changing their sizes, shapes, or surface chemistries - to match a specific medical application or target. In addition to this, nanoparticles undergo the enhanced permeability and retention (EPR) effect; a phenomenon where they naturally accumulate in tumour tissues due to the leaky nature of tumour blood vessels. This effect improves the targeting precision, and drugs can be delivered more efficiently to cancer cells, while sparing healthy ones one, avoiding unnecessary damage and side effects to the patient.

While drug delivery is a major focus, nanomedicine research also plays a role in diagnostics. Nanoparticles can be engineered to function as contrast agents in medical imaging, helping doctors detect diseases earlier and monitor treatments more accurately. There is also a growing interest in using nanomaterials for tissue regeneration, by creating scaffolds that support the repair and regrowth of damaged tissues.

As research continues, nanomedicine holds promise for tacking some of the most pressing challenges in modern healthcare - from treating cancer more safely to developing new vaccines and personalised therapies. Though there are some hurdles, particularly around large-scale manufacturing and regularly approval, the path ahead for nanomedicine has huge potential.

As the field of nanomedicine continues to grow, it shows great promise in reshaping healthcare with treatments that are smarter, safer, and more effective - ultimately improving patient outcomes and transforming the way we fight disease.

Written by Saanchi Agarwal

Related articles: Nanomedicine / Nanoparticles and diabetes treatment / Nanoparticles and health / Nanogels